Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10577094	
Filing Date		2006-04-26	
First Named Inventor	Dietrr	nar KRAUTWURST	
Art Unit			_
Examiner Name			_
Attorney Docket Numb	or	102790-211/30246US	_

	U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wisl	h to a	id additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant		Relev	s,Columns,L ant Passage es Appear		
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d butto			
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³			e or	Pages,Colu where Rele Passages o Figures App	vant r Relevant	+4			
	1										
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
			NON	-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s),							Тs			

Application Number 10577094 |
Fing Date 2006-04-26 |
First Named Inventor | Debmar KRAUTWURST |
Art Unit |
Examiner Name |
Attorney Docket Number | 102790-211/30248US

1	Szekeres PG. Functional assays for identifying ligands at orphan G protein-coupled receptors. Receptors Channels. 2002;8(5-6):297-308	
2	Wilson S, Bergama DJ, Chambers JK, Mair AI, Fanton KG, Ellis C, Maudock PR, Herrity NC, Stade HM. Orphan G- protein-coupled receptors: the next generation of drug targets? Br J Pharmacol. 1998 Dec;125(7):1387-92	
3	Shaaban S, Benton B. Orphan G protein-coupled receptors: from DNA to drug targets. Curr Opin Drug Discov Devel. 2001 Sep.4(5):335-47	
4	Joost P, Methner A. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. Genome Biol. 2002 Oct 17;3(11):RESEARCH0063.	
5	Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weiler JR, Wright AC, Bergmann JE, Gatanaris GA. The G protein-coupled receptor repertores of human and mouse. Proc Natl Acad Sci	
6	Lucas KA, et al. Guanylyl Cyclases and Signaling by Cyclic GMP. Pharmacol Rev. 2000 Sep;52(3):375-414.	
7	Gibson AD, Garbers DL. Guanyfyl cyclases as a family of putative odorant receptors. Annu Rev Neurosci. 200;23:417-39.	
8	Matsursmi H, Armein H, Taste and pheromone perception in mammals and files. Genome Biol. 2003;4(7):220. Epub 2003 Jun 30	
9	Dulac C, Torello AT. Molecular detection of pheromone signals in mammals: from genes to behavior. Nat Rev Neurosci. 2003. Jul.4(7):551-62.	
10	Koshimizu TA, et al. Recent progress in alpha 1-adrenoceptor pharmacology. Biol Pharm Bull. 2002 Apr;25 (4):401-8.	
11	Araneda R. C., Klni A. D. and Firestein S. (2000) The molecular receptive range of an odorant receptor. Nat Neurosci, 3, 1248-55.	

12	Bakalyar H. A. and Reed R. R. (1990) Identification of a specialized adenyityl cyclase that may mediate odorant detection. Science 250, 1403-6.	
13	Baker H., Cummings D. M., Munger S. D., Margolis J. W., Franzen L., Reed R. R. and Margolis F. L. (1999) Targeted deletion of a cyclic nucleotise-gated channel subunit (OCNC1); biochemical and morphological consequences in adult mice. J. Neurosci, 19, 9313-21.	
14	Bellusco L, Gold G.H., Nemes A. and Axel R. (1998) Mice deficient in G(off) are anosmic. Neuron, 20, 69-81.	
15	Bozza J., Feinstein P., Zheng C. and Mornbeerts P. (2002) Odorant receptor expression defines functional units in the mouse offactory system. J Neurosco, 22, 3033-43.	
16	Brunet L.J., Gold G.H. and Ngai J. (1996) General anosmis caused by a targeted disruption of the mouse oifactory cyclic nucleotide-gated cation channel. Neuron 7, 681-93.	
17	Buck L and Axel R. (1991) A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. Cell, 65, 175-87.	
18	Bufe B., Hofmann T., Krauhvurst D., Raguse J.D. and Meyerhof W. (2002) The human TAS2R16 receptor mediates bitter taste in response to beta-glucopyranosides. Nat Genet 32, 397-40.	
19	Chandrashekar J., Mueller K.L., Hoon M.A., Adler E., Feng L., Guo W., Zuker C.S., and Ryba N.J. (2000) T2Rs function as bitter taste receptors. Cell, 100, 703-11.	
20	Chess A, Smon I, Cedar H, and Axel R (1994) Allelic inactivation regulates offactory receptor gene expression. Cell, 78, 823-34.	
21	Choi E.J., Xia Z. and Storm D.R. (1992) Stimulation of the type III offactory adentylyl cyclase by calcium and calmodulin. Biochemistry, 31, 6462-8.	
22	Crider J.Y. and Sharif N.A. (2002) Adenylyl cyclase activity mediated by beta-adrenoceptros in immortalized human trabocular meshwork and non-pugnented citiary epithelial cells. J Oou Pharmacol Ther, 18, 221-30.	

| Application Number | 105/7094 | Filing Date | 2006-04-26 | Filing Date |

23	Dhallan R.S., Yau K.W., Schrader K.A. and Reed R.R. (1990) Primary structure and functional expression of a cyclic nucleotide-activated channel from offactory neurons. Nature, 347, 184-7.	
24	Duchamp-Viret P., Duchamp A. and Chaput M.A. (2000) Peripheral odor coding in the rat and frog: quality and intensity specification. J Neurosci, 20, 2383-90.	
25	Dzeja C., Hagen V., Kaupp U.B. and Frings S. (1999) Ca2+ permeation in cyclic nucleotide-gated channels. Embo J. 18, 131-44.	
26	Finn J.T., Krautwurst D., Schroeder J.E., Chen J.Y., Reed R.R. and Yau K.W. (1989) Functional co-assembly among subunits of cyclic-suscibidide-activated, nonselective cation channels, and across species from nematode to human. Bophys J, 74, 1333-45.	
27	Firestein S., Darrow B. and Shepherd G.M. (1991) Activation of the sensory current in salamander offactory receptor neurons depends on a G protein-mediated cAMP second messenger system. Neuron, 6, 825-35.	
28	Fulls, H.J., Vassar, R., Foster, D.C., Yang, R.B., Axet, R. and Garbers, D.L. (1995) A receptor guarnyyl cyclese expressed specifically in offsclory sensory neurons. Proc Natl Acad Sci USA 92, 3571-5.	
29	Gallard I., Rouquier S., Pin J.P., Molard P., Richard S., Bamabe C., Demaille J. and Giorgi D. (2002) A single offsctory receptor specifically blinds a set of odorant molecules. Eur J Neurosci, 15, 409-18.	
30	Glusman G., Sosnaky A., Ben-Asher E., Avkian N., Sonkin D., Bahar A., Rosenthal A., Clifton S., Roe B., Ferraz C., Demaille J. and Lancet D. (2000) Sequence, structure, and evolution of a complete human offactory receptor gene cluster. Genomics, 63, 227-45.	
31	Gold, G.H. (1999) Controversall issues in vertebrale offactory transduction. Annu Rev Physiol, 61, 857-71.	
32	Grosch W. (2001) Evaluation of the key odorants of foods by dilution experiments, aroma models and omission. Chem Senses, 26, 533-45.	
33	Hamana H., Hirono J., Küzumi M. and Sato T. (2003) Sensitivity-dependent Hierarchical Receptor Codes for Odors, Chem Senses. 28, 87-104.	

| Application Number | 105/7094 | Find Date | 2006-04-26 | Find Date |

34	Hargrave P.A., Adamus G., Arendt A., McDowell J.H., Wang J., Szaby A., Curlis D. and Jackson R.W. (1986) Rhodopsin's amino terminus is a principal antigenic site. Exp. Eye Res. 42, 363-73.	
35	Jones D.T., Masters S.B., Bourne H.R. and Reed R.R. (1990) Blochemical characterization of three stimulatory GTP- briding proteins. The large and small forms of Gs and the olfactory-specific G-protein. Golf. J Biol Chem.	
36	Jones D.T. and Reed R.R. (1989) Golf: an offactory neuron specific-G protein involved in odorant signal transduction. Science, 244, 790-5.	
37	Julis D.M., Fulle H.J., zhao A.Z., Houslay M.D., Garbers D.L. and Beavo J.A. (1997). A subset of offactory neurons that selectively express CGMP-stimulated phosphodiesterase (PDE2) and guarrylyl cyclase-D define a unique	
38	Kawai F. (1999) Odorants suppress T- and L-type Ca2+ currents in offactory receptor cells by shifting their inactivation curves to a negative voltage [In Process Citation]. Neurosci Res, 35, 253-63.	
39	Krauhwurst D., Yau K.W. and Reed R.R. (1998) Identification of ligands for offsctory receptors by functional expression of a receptor library. Cell, 95, 917-26.	
40	Kurahashi J., Lowe G. and Gold G.H. (1994) Suppression of odorant responses by odorants in olfactory receptor cells. Science, 265, 118-20.	
41	Lapidot X., Pipel Y., Gliad Y., Falcovitz A., Sharon D., Haaf J. and Lancet D. (2001) Mouse-human orthology relationships in an olfactory receptor gene cluster. Genomics, 71, 296-306.	
42	Leffingwell J.C. (2003) Chirality & Odour Perception — Acyclic Terpenoid Odorants. http://www.leffingwell.com/ chirality/acyclic_terpenoid.htm	
43	Lu H.Y., Wenzel Selfert K. and Selfert R. (2001). The olfactory G protein G(alphacif) possesses a lower GDP-atfinity and deactivates more rapidly than G(salphashort); consequences for receptor-coupling and adenylyl cyclase activation. J Neurochem, 78, 325-38.	
44	Lucas K.A., Pitari G.M., Kazerounian S., Ruiz-Slewart I., Park J., Schulz: S., Chepenik K.P. and Waidman S.A. (2000) Granylyi cyclasses and signaling by cyclic GMP. Pharmacol Rev., 52, 375-414.	

Application Number 1057/094 Filing Date 2006-04-26 Filing Date 2006-04-26 Filing Date 1057/094 Filing Date 1057/09

	45	Ludwig J., Margalit J., Esmann E., Lancet D. and Kaupp U.B. (1990) Primary structure of cAMP-gated channel from bovine olfactory epithelium. FEBS Lett, 270, 24-9.					
	46	Malvl. and Shepherd G.M. (2000) Functional mosaic organization of mouse offactory receptor neurons. Proc Natl Acad Sci USA, 97, 12869-74.					
	47	Malnic B., Hirono J., Sato T. and Buck L.B. (1999) Combinatorial receptor codes for odors. Cell, 96, 713-23.					
	48	Meyer M.R., Angele A., Kremmer E., Kaupp U.B. and Muller F. (2000) A cGMP-signaling pathway in a subset of offactory neurons. Proc Natl Acad Sci USA, 97, 10595-500.					
	49	Mombeerts P. (1999) Molecular biology of odorant receptors in vertebrates. Annu Rev Neurosci, 22, 487-509.					
	50	Nakamura T. and Gold G.H. (1987) A cyclic nucleotide-gated conductance in olfactory receptor cilia. Nature, 325, 442-4.					
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add						

EXAMINER SIGNATURE

Examiner Signature

Date Considered

Date Considered

"EXAMINER: nitial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through a citation find in conformance and not considered. Include copy of this form with next communication to accilicant.

1 See Kind Codes of USPTO Potent Documents at swery USPTO COD's or METP 981.04. 2 Enter office that issued the document, by the two-later code (WIDO Standard ST3.) 3 for Justonese potent outcomest, the includes on the year of the inspire of the Emport amenge precise the serial number of the plant for serial of the Comparts and precise the serial number of the plant for serial number of the plant for serial or the comparts are not serial or the comparts and the comparts are not serial number of the plant for serial numb

Application Number 1057094 | 1057094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094 | 1157094

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew N. Parfomak/	Date (YYYY-MM-DD)	2006-10-13
Name/Print	Andrew N. Parfornak	Registration Number	32431

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.